Key result
Phenotype-based antiviral discovery system integrates early compound screening and target identification using an EV71 model.
Why the study?
Resistance to current antiviral drugs and the emergence of new viral infections have increased the demand for new antiviral strategies and reagents.
Offers an integrated in vitro antiviral discovery platform; leaves open clinical translation and in vivo validation.
The prevalence of chronic viral infectious diseases, the emergence and re-emergence of new viral infections, and in particular, resistance to currently used antiviral drugs have led to increased demand for new antiviral strategies and reagents. Increased understanding of the molecular mechanisms of viral infection has provided great potential for the discovery of new antiviral agents that target viral proteins or host factors. In this work, we introduce a comprehensive system using enteroviruses 71 (EV71) as an example for leading compound discovery to develop new antiviral.
No takes yet. Share an insight, caveat, or question.
Cao et al. (2015) studied Enterovirus 71 (EV71) infection. Phenotype-based antiviral discovery system was evaluated. A comprehensive phenotype-based antiviral discovery system using EV71 as a model integrates early compound screening, target identification, and mechanism investigation through various in vitro assays.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: